CORT · XBRL financial data

Corcept Therapeutics financial statements, every quarter

The same tables from 12 filings, lined up. Matched by XBRL tag: renamed lines keep their history.

How these numbers work

Every number comes from the company's XBRL financial data filed with the SEC, and each one links to its filing.
Lines are matched by XBRL tag, so a line renamed between filings keeps its history.
* marks a quarter worked out from the filing totals: the 10-K year minus the first three quarters, or a year-to-date total minus the earlier one. Fourth-quarter earnings per share is fourth-quarter net income over the fourth-quarter weighted shares.
0 means a filing states zero; a dash (—) means no filing states that number.
“year only” means the 10-K gives the full year but not the quarters needed to work out the fourth. A worked-out quarter of revenue, cost of revenue or operating cash flow more than twice the company's largest quarter of the two years before is shown this way too.
Gross profit is shown as the company reports it; a worked-out quarter must equal revenue less cost of revenue for that quarter, or it is a dash.
Operating income can be above gross profit when the company books other operating income between the two, shown on its own line.
Shares outstanding come from each filing's cover page, as of the date printed there.
Quarters are fiscal: Q2 FY27 is the second quarter of the company's fiscal 2027.

Income statement

Fiscal quarters (CORT's year ends in late December)

In millions of dollars	Q4 FY23Dec 31, 2023	Q1 FY24Mar 31, 2024	Q2 FY24Jun 30, 2024	Q3 FY24Sep 30, 2024	Q4 FY24Dec 31, 2024	Q1 FY25Mar 31, 2025	Q2 FY25Jun 30, 2025	Q3 FY25Sep 30, 2025	Q4 FY25Dec 31, 2025	Q1 FY26Mar 31, 2026	Q2 FY26Jun 30, 2026	Q3 FY26Sep 30, 2026
Revenue from contracts with customers	135*	147	164	183	182*	157	194	208	202*	165	256	340
Cost of goods and services sold	2*	3	3	3	3*	2	3	5	3*	3	4	5
Research and development	55*	59	59	59	70*	61	60	69	65*	66	54	57
Selling, general and administrative	47*	56	67	74	83*	91	104	124	130*	145	157	164
Operating income (loss)	32*	30	36	47	25*	3	27	10	4*	(50)	41	115
Income tax expense (benefit)	5*	7	6	6	1*	(11)	(3)	(4)	(14)*	(13)	3	(6)
Net income (loss)	31*	28	35	47	31*	21	35	20	24*	(32)	43	127
Earnings per share, basic USD per share	0.31*	0.27	0.34	0.45	0.30*	0.19	0.33	0.19	0.23*	(0.30)	0.40	1.17
Earnings per share, diluted USD per share	0.28*	0.25	0.32	0.41	0.26*	0.17	0.29	0.16	0.20*	(0.30)	0.36	1.01
Weighted average shares, basic millions of shares	102*	103	103	103	104*	104	104	104	104*	104	105	107
Weighted average shares, diluted millions of shares	111*	110	111	114	119*	120	120	119	120*	104	118	123

Fiscal quarters (CORT's year ends in late December)

In millions of dollars	Q4 FY23Dec 31, 2023	Q1 FY24Mar 31, 2024	Q2 FY24Jun 30, 2024	Q3 FY24Sep 30, 2024	Q4 FY24Dec 31, 2024	Q1 FY25Mar 31, 2025	Q2 FY25Jun 30, 2025	Q3 FY25Sep 30, 2025	Q4 FY25Dec 31, 2025	Q1 FY26Mar 31, 2026	Q2 FY26Jun 30, 2026	Q3 FY26Sep 30, 2026
Cash and cash equivalents	136	150	129	137	128	90	103	125	120	109	111	99
Marketable securities	233	261	345	243	256	233	239	297	252	229	197	272
Marketable securities, non-current	57	40	19	167	220	248	173	103	160	177	236	292
Accounts receivable	41	62	54	60	54	62	65	70	60	39	77	111
Inventory	8	7	8	8	12	14	12	12	13	13	13	12
Prepaid and other current assets	28	24	26	19	22	40	24	37	41	36	41	40
Total current assets	459	503	561	467	472	439	443	541	485	426	440	534
Property and equipment, net	0	0	1	3	3	3	2	2	2	3	5	5
Right-of-use asset	0	0	6	6	5	5	5	5	5	7	7	7
Total assets	622	656	715	784	841	846	802	824	837	815	889	1,034
Accounts payable	17	13	19	19	15	28	24	34	40	33	15	22
Accrued liabilities	52	60	59	79	91	89	91	108	91	80	115	136
Total current liabilities	105	97	101	126	141	143	145	172	166	149	154	178
Lease liability, non-current	0	—	6	6	6	6	6	5	5	8	8	7
Total liabilities	115	108	118	145	161	163	166	192	189	177	183	200
Retained earnings	403	430	466	513	544	564	599	619	643	612	655	781
Total stockholders' equity	507	548	596	639	680	683	636	632	648	638	706	834
Total liabilities and equity	622	656	715	784	841	846	802	824	837	815	889	1,034
Common shares outstanding (cover page) millions of shares	104	104	104	105	106	106	105	105	106	107	108	109

Fiscal quarters (CORT's year ends in late December)

In millions of dollars	Q4 FY23Dec 31, 2023	Q1 FY24Mar 31, 2024	Q2 FY24Jun 30, 2024	Q3 FY24Sep 30, 2024	Q4 FY24Dec 31, 2024	Q1 FY25Mar 31, 2025	Q2 FY25Jun 30, 2025	Q3 FY25Sep 30, 2025	Q4 FY25Dec 31, 2025	Q1 FY26Mar 31, 2026	Q2 FY26Jun 30, 2026	Q3 FY26Sep 30, 2026
Net income (loss)	31*	28	35	47	31*	21	35	20	24*	(32)	43	127
Stock-based compensation	13*	13	15*	16*	17*	22	19*	23*	21*	23	29*	29*
Depreciation and amortization	0*	0	0*	0*	0*	0	0*	0*	0*	1	1*	1*
Net cash from operating activities	6*	24	41*	74*	59*	5	44*	54*	38*	(17)	34*	143*
Purchases of property and equipment	0*	0	0*	2*	0*	0	0*	0*	0*	0	3*	1*
Net cash from investing activities	17*	(9)	(60)*	(44)*	(64)*	(3)	70*	15*	(12)*	5	(29)*	(132)*
Proceeds from issuing equity	2*	—	—	—	—	—	—	—	—	—	—	—
Share repurchases	(145)*	0	3*	12*	0*	27	103*	42*	0*	0	0*	6*
Net cash from financing activities	1*	(1)	(2)*	(21)*	(5)*	(40)	(103)*	(46)*	(31)*	1	(2)*	(24)*
Net change in cash	24*	14	(21)*	9*	(10)*	(38)	13*	22*	(5)*	(12)	2*	(13)*

SIC 2834 and related industry codes, similar size. Each row is the latest quarter reported.

How peers are chosen

SIC 2834 and related industry codes with public float (or, where float is missing, quarterly revenue) between 0.2x and 5x the company's.
Each row is the latest quarter the company has reported, named in the Quarter column; when that filing is a 10-K, it is the fourth quarter, never the full year.
Runway shows only for companies burning cash with under $10B of public float.
* marks a quarter worked out from the filing totals: for a 10-Q, the year-to-date total less the earlier one.
A cell reading “not reported” means the filings give no figure for that quarter alone.

Company	Cash ($M)	Revenue, quarter ($M)	Operating cash flow, quarter ($M)	Shares outstanding	Runway	Quarter
Corcept Therapeutics	99	340	143*	109.4M	—	Q3 FY26 10-QSep 30, 2026
Repligen	727	209	43*	63.9M	—	Q3 FY26 10-QSep 30, 2026
Jazz Pharmaceuticals	2,036	1,243	506*	64.2M	—	Q3 FY26 10-QSep 30, 2026
Madrigal Pharmaceuticals	515	431	121*	23.2M	—	Q3 FY26 10-QSep 30, 2026
Biomarin Pharmaceutical	736	1,025	188*	193.7M	—	Q3 FY26 10-QSep 30, 2026
Revolution Medicines	815	not reported	(387)*	214.3M	10.2 quarters	Q2 FY26 10-QJun 30, 2026
Ionis Pharmaceuticals	350	268	566*	166.2M	—	Q2 FY26 10-QJun 30, 2026
Alkermes	631	480	93*	168.0M	—	Q3 FY26 10-QSep 30, 2026
Halozyme Therapeutics	163	481	241*	113.5M	—	Q2 FY26 10-QJun 30, 2026

Not investment advice. Not affiliated with the U.S. SEC.